RLYB
NASDAQ HealthcareRallybio Corporation - Common Stock
Biotechnology
Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. The company has a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases, as well as collaboration agreement with Johnson & Johnson to provide therapeutic solutions for pregnant individuals at risk of fetal and neonatal alloimmune thrombocytopenia. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.
�� 市场数据
| 价格 | $16.23 |
|---|---|
| 成交量 | 180,041 |
| 市值 | 94.13M |
| RSI（14日） | 65.7 |
| 200日均线 | $6.95 |
| 50日均线 | $11.10 |
| 52周最高 | $17.57 |
| 52周最低 | $2.16 |
| Forward P/E | -3.01 |
| Price / Book | 1.71 |
🎯 投资策略评分
RLYB 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🎈 Over-Hyped (78/100) — 此策略 超买股票（潜在做空标的）.
评分最低的策略： 🐋 Institutional Whale (2/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 RLYB in your text
粘贴任何文章、记录或帖子 — 工具将提取 RLYB 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-06-02.